These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15600382)

  • 61. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.
    Stigler KA; Potenza MN; Posey DJ; McDougle CJ
    Paediatr Drugs; 2004; 6(1):33-44. PubMed ID: 14969568
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Do serum lipids predict response to clozapine treatment?
    Procyshyn RM; Honer WG; Barr AM
    J Psychiatry Neurosci; 2009 Mar; 34(2):168. PubMed ID: 19270766
    [No Abstract]   [Full Text] [Related]  

  • 63. Long-term treatment with atypical antipsychotics and risk of weight gain.
    Stip E; Anselmo K; Wolfe M; Lessard C; Landry P
    Drug Saf; 2006; 29(6):550-2; author reply 552. PubMed ID: 16752937
    [No Abstract]   [Full Text] [Related]  

  • 64. Antipsychotic drugs and schizophrenia.
    Duan N; Kraemer HC; Mintz J
    N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422019
    [No Abstract]   [Full Text] [Related]  

  • 65. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.
    Chue P
    Can J Psychiatry; 2004 Mar; 49(3):200-7. PubMed ID: 15101503
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sleep apnea associated with antipsychotic-induced obesity.
    Wirshing DA; Pierre JM; Wirshing WC
    J Clin Psychiatry; 2002 Apr; 63(4):369-70. PubMed ID: 12000215
    [No Abstract]   [Full Text] [Related]  

  • 67. The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.
    Jacobowitz W; Derbabian B; Saunders A
    J Psychosoc Nurs Ment Health Serv; 2014 Jul; 52(7):30-7. PubMed ID: 24766105
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.
    Newcomer JW; Nasrallah HA; Loebel AD
    J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association between Serum Lipids and Antipsychotic Response in Schizophrenia.
    Kim DD; Barr AM; Fredrikson DH; Honer WG; Procyshyn RM
    Curr Neuropharmacol; 2019; 17(9):852-860. PubMed ID: 30819084
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.
    Balf G
    Am J Psychiatry; 2008 Sep; 165(9):1206-7; author reply 1207. PubMed ID: 18765500
    [No Abstract]   [Full Text] [Related]  

  • 71. Weight gain from novel antipsychotic drugs: need for action.
    Green AI; Patel JK; Goisman RM; Allison DB; Blackburn G
    Gen Hosp Psychiatry; 2000; 22(4):224-35. PubMed ID: 10936629
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics.
    Leitão-Azevedo CL; Guimarães LR; de Abreu MG; Gama CS; Lobato MI; Belmonte-de-Abreu PS
    Braz J Psychiatry; 2006 Dec; 28(4):301-4. PubMed ID: 17242810
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.
    Li R; Zhang Y; Zhu W; Ding C; Dai W; Su X; Dai W; Xiao J; Xing Z; Huang X
    Sci Rep; 2020 Oct; 10(1):17028. PubMed ID: 33046806
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
    Remington G
    Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
    [No Abstract]   [Full Text] [Related]  

  • 75. Considerations regarding the use of metformin with olanzapine.
    Alamiri B
    Am J Psychiatry; 2008 Sep; 165(9):1205-6; author reply 1207. PubMed ID: 18765498
    [No Abstract]   [Full Text] [Related]  

  • 76. Atypical antipsychotic induced weight gain: pathophysiology and management.
    Ananth J; Venkatesh R; Burgoyne K; Gadasalli R; Binford R; Gunatilake S
    Ann Clin Psychiatry; 2004; 16(2):75-85. PubMed ID: 15328901
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.
    Henderson DC
    J Clin Psychiatry; 2008 Feb; 69(2):e04. PubMed ID: 18363448
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia.
    Quek YF; See YM; Yee JY; Rekhi G; Ng BT; Tang C; Lee J
    Asian J Psychiatr; 2022 Aug; 74():103192. PubMed ID: 35751958
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Atypical antipsychotic weight gain: a major clinical challenge.
    Sharpe JK; Hills AP
    Aust N Z J Psychiatry; 2003 Dec; 37(6):705-9. PubMed ID: 14636385
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Olanzapine use in a patient with schizophrenia and the risk of diabetes.
    Folnegović-Smalc V; Jukić V; Kozumplik O; Mimica N; Uzun S
    Eur Psychiatry; 2004 Feb; 19(1):62-4. PubMed ID: 14969784
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.